KeyCorp Comments on CryoPort’s FY2028 Earnings (NASDAQ:CYRX)

CryoPort, Inc. (NASDAQ:CYRX – Free Report) – Equities researchers at KeyCorp issued their FY2028 earnings estimates for shares of CryoPort in a report issued on Thursday, November 5th. KeyCorp analyst P. Knight anticipates that the company will post earnings of ($0.26) per share for the year. KeyCorp has an “Overweight” rating and a $20.00 price objective on the stock. The consensus estimate for CryoPort’s current full-year earnings is ($0.88) per share.

CYRX has been the subject of a number of other reports. Roth Capital restated a “buy” rating and set a $21.00 price target on shares of CryoPort in a report on Friday, August 7th. Piper Sandler raised CryoPort to a “buy” rating in a report on Tuesday, October 13th. BTIG Research upped their price objective on CryoPort from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Robert W. Baird set a $26.00 target price on shares of CryoPort in a report on Tuesday, October 13th. Finally, Guggenheim raised their target price on shares of CryoPort from $16.00 to $19.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $21.69.

Read Our Latest Stock Analysis on CYRX

CryoPort Price Performance

Shares of CYRX stock traded down $0.21 during trading hours on Friday, hitting $19.89. The stock had a trading volume of 406,849 shares, compared to its average volume of 1,284,760. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of -20.50 and a beta of 1.89. CryoPort has a one year low of $7.61 and a one year high of $21.78. The stock’s 50-day moving average price is $17.43 and its two-hundred day moving average price is $13.70.

CryoPort (NASDAQ:CYRX – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The company had revenue of $50.22 million for the quarter, compared to the consensus estimate of $48.66 million. CryoPort had a negative net margin of 21.46% and a negative return on equity of 8.28%.

Insider Transactions at CryoPort

In other CryoPort news, Director Daniel Hancock sold 74,379 shares of the company’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $20.21, for a total transaction of $1,503,199.59. Following the sale, the director directly owned 69,052 shares in the company, valued at $1,395,540.92. This represents a 51.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark W. Sawicki sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $19.93, for a total value of $199,300.00. Following the sale, the insider owned 92,356 shares in the company, valued at approximately $1,840,655.08. This trade represents a 9.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 9.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CryoPort

Large investors have recently modified their holdings of the stock. Roubaix Capital LLC increased its position in CryoPort by 12.4% during the third quarter. Roubaix Capital LLC now owns 454,926 shares of the company’s stock valued at $7,916,000 after acquiring an additional 50,148 shares during the last quarter. White Pine Capital LLC purchased a new stake in shares of CryoPort in the third quarter valued at $539,000. Royce & Associates LP purchased a new stake in shares of CryoPort in the third quarter valued at $7,073,000. Diversified Trust Co raised its stake in shares of CryoPort by 3.4% in the third quarter. Diversified Trust Co now owns 19,769 shares of the company’s stock valued at $344,000 after acquiring an additional 657 shares during the period. Finally, Russell Investments Group Ltd. lifted its holdings in shares of CryoPort by 376.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 399,047 shares of the company’s stock worth $6,943,000 after acquiring an additional 315,343 shares during the last quarter. Institutional investors own 92.90% of the company’s stock.

CryoPort Company Profile

(Get Free Report)

Cryoport, Inc. provides temperature-controlled supply chain services for the life sciences industry. Its offerings support the development and commercial distribution of cell and gene therapies, biologics, reproductive medicine products and other temperature-sensitive materials. The company’s services include specialized shipping systems and packaging, transportation management, cryogenic storage, shipment monitoring and logistics support. These solutions are designed to help customers maintain required conditions and manage the handling of sensitive materials across clinical and commercial supply chains.

Read More

Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.